Drug
Isis Eif4e RX
Isis Eif4e RX: highest development phase Phase 1/2, developed by Ionis Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Ionis Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ISIS EIF4E Rx NCT01234038 | Phase 1/2 | Non-small Cell Lung Cancer |
| ISIS EIF4E Rx NCT01234025 | Phase 1/2 | Castrate-Resistant Prostate Cancer |
Latest
No recent events.
Follow Isis Eif4e RX on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.